Skip to main content
. 2019 Jun 8;16:453–467. doi: 10.1016/j.isci.2019.06.001

Figure 2.

Figure 2

Ectopic Expression of Anaplastic Lymphoma Kinase (ALK) in Melanoma Conferred Resistance to BRAF Inhibitor

(A) BRAF-mutant melanoma cells A375, M229, and SKMEL-28 ectopically expressing an empty vector (EV) or ALK expression construct were treated with either DMSO or the indicated concentrations of vemurafenib. Relative cell survival (%) for each cell line in reference to DMSO-treated cells is shown.

(B) BRAF-mutant melanoma cells A375, M229, and SKMEL-28 ectopically expressing an empty vector (EV) or ALK were treated with either DMSO or the indicated concentrations of dabrafenib. Relative cell survival (%) for each cell line in reference to DMSO-treated cells is shown.

(C) A375 cells ectopically expressing empty vector (EV) or ALK expression construct were treated with 2 μM vemurafenib for 4 weeks. Images of representative plates with surviving colonies are shown. Scale bar, 200 μM.

Data are presented as mean ± SD. **p < 0.01, ***p < 0.001. See also Figure S1.